Indication

Add-on therapy in patients aged 5 years and older with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.

Medicine details

Medicine name:
belimumab (Benlysta)
SMC ID:
SMC2477
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
TBC